Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Thermal ablation compared to stereotactic body radiation therapy for hepatocellular carcinoma: A multicenter retrospective comparative study
Kim, Hannah P. , Singal, Amit G. , Owen, Dawn , Parikh, Neehar D. , Rose, Steven C., McGinty, Katrina , Agala, Chris B. , Burke, Lauren M. , Abate, Anjelica, Do, John, Folkert, Michael R. , Forbes, C.D., Hattangadi‐Gluth, Jona A. , Hayashi, Paul H. , Jones, Keri, Lawrence, Theodore S. , Maurino, C. , Mayo, Charles S. , Pak, Taemee , Patil, Preethi, Simpson, Daniel R. , Tepper, Joel E. , Thapa, Diwash , Moon, Andrew M , Singal, Amit , Owen, Dawn , Parikh, Neehar D , McGinty, Katrina A , Burke, Lauren M , Altun, Ersan , Folkert, Michael R , Hayashi, Paul H , Khatri, Gaurav , Kono, Yuko , Lawrence, Theodore S , Tepper, Joel E , Gerber, David A , Mendiratta-Lala, Mishal , Beyer, Christian, Forbes, Chalon, Khatri, Gaurav , Mauro, David M. , Sanders, Emily C. , Yanagihara, Ted K. , Wang, Kyle , Gerber, David A.

Mayo Clinic

Hepatology Communications | June 14, 2023 | Volume: 7 | Issue: 7 | Pages: No page available

10.1097/hc9.0000000000000184 | PMID 37314737 Get It

Background & Aims: Early-stage HCC can be treated with thermal ablation or stereotactic body radiation therapy (SBRT). We retrospectively compared local progression, mortality, and toxicity among patients with HCC treated with ablation or SBRT in a multicenter, US cohort. Approach & Results: We included adult patients with treatment-naïve HCC lesions without vascular invasion treated with thermal ablation or SBRT per individual physician or institutional preference from January 2012 to December 2018. Outcomes included local progression after a 3-month landmark period assessed at the lesion level and overall survival at the patient level. Inverse probability of treatment weighting was used to account for imbalances in treatment groups. The Cox proportional hazard modeling was used to compare progression and overall survival, and logistic regression was used for toxicity. There were 642 patients with 786 lesions (median size: 2.1 cm) treated with ablation or SBRT. In adjusted analyses, SBRT was associated with a reduced risk of local progression compared to ablation (aHR 0.30, 95% CI: 0.15–0.60). However, SBRT-treated patients had an increased risk of liver dysfunction at 3 months (absolute difference 5.5%, aOR 2.31, 95% CI: 1.13–4.73) and death (aHR 2.04, 95% CI: 1.44–2.88, p < 0.0001). Conclusions: In this multicenter study of patients with HCC, SBRT was associated with a lower risk of local progression compared to thermal ablation but higher all-cause mortality. Survival differences may be attributable to residual confounding, patient selection, or downstream treatments. These retrospective real-world data help guide treatment decisions while demonstrating the need for a prospective clinical trial.
Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis
Tepper, Stewart J. , Kudrow, David, Ashina, Messoud , Reuter, Uwe , Dodick, David W. , Wang, Andrea , Cheng, Sunfa , Klatt, Jan , Mikol, Daniel D., Ashina, Messoud , Dodick, David W , Reuter, Uwe , Lipton, Richard B. , Silberstein, Stephen D.

Mayo Clinic

Headache: The Journal of Head and Face Pain | June 14, 2023 | Volume: 63 | Issue: 6 | Pages: 730-742

10.1111/head.14536 | PMID 37313616 Get It

Abstract Objective Assess the long‐term efficacy and safety of erenumab in patients with chronic migraine with acute medication overuse. Background Overuse of acute medication in patients with chronic migraine has been linked to greater pain intensity and disability and may diminish the effectiveness of preventive therapies. Methods This 52‐week open‐label extension study followed a 12‐week double‐blind placebo‐controlled study in which patients with chronic migraine were randomized 3:2:2 to placebo or once‐monthly erenumab 70 mg or 140 mg. Patients were stratified by region and medication overuse status. Patients received erenumab 70 mg or 140 mg throughout or switched from erenumab 70 to 140 mg (based on protocol amendment to augment safety data at higher dose). Efficacy was assessed in patients with and without medication overuse at parent study baseline. Results Of 609 patients enrolled in the extension study, 252/609 (41.4%) met the criteria for medication overuse at parent study baseline. At Week 52, the mean change in monthly migraine days from parent study baseline was −9.3 (95% confidence interval: −10.4, −8.1 days) in the medication overuse subgroup versus −9.3 (−10.1, −8.5 days) in the non‐medication overuse subgroup (combined erenumab doses); proportion of patients achieving ≥50% reduction in monthly migraine days at Week 52 was 55.9% (90/161; 48.2%, 63.3%) versus 61.3% (136/222; 54.7%, 67.4%), respectively. Among baseline users of acute migraine‐specific medication, the mean change in monthly migraine‐specific medication days at Week 52 was −7.4 (−8.3, −6.4 days) in the medication overuse subgroup versus −5.4 (−6.1, −4.7 days) in the non–medication overuse subgroup. Most patients (197/298; 66.1%) in the medication overuse subgroup transitioned to non‐overuse status by Week 52. Erenumab 140 mg was associated with numerically greater efficacy than erenumab 70 mg across all endpoints. No new safety signals were identified. Conclusion Long‐term erenumab treatment demonstrated sustained efficacy and safety in patients with chronic migraine with and without acute medication overuse.
ON THE DESIGN OF A NOVEL PHONOENTEROGRAM SENSING DEVICE USING AI ASSISTED COMPUTER-AIDED AUSCULTATION
Damani, Shivam, Damani, Devanshi N. , Redij, Renisha, Sethi, Arshia , Muddaloor, Pratyusha, Kapoor, Anoushka, Rajagopal, Anjali , Gopalakrishnan, Keerthy, Chedid, Victor , Ryu, Alexander J. , Aakre, Christopher A. , Arunachalam, S P , Chedid, Victor G , Wang, Xiao‐Jing , Ryu, Alexander J. , Arunachalam, Shivaram P.

Mayo Clinic

2023 Design of Medical Devices Conference | June 12, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/dmd2023-7977 Get It

Abstract Bowel sounds have been previously used to study intestinal motility and overall digestive health in various clinical settings. However, the blurred definition of bowel sounds and their subtypes, limited resources for interpretation, poor sensitivity, and low positive predictive value led to their restricted utility. Recent advances in artificial intelligence and machine learning have steered interest in developing unique tools using the phonoenterogram to analyze diverse bowel sounds. In our study, bowel sounds were recorded from eight healthy volunteers using the Eko Duo stethoscope. A novel deep-learning algorithm was designed to classify the recordings into baseline or prominent bowel sounds. A total of 11,210 data points (5,605 balanced sounds) were used to train and test the model to yield an accuracy of 0.895, a precision of 0.890, and a recall of 0.854 reflecting successful segregation of these sounds into respective groups. More extensive studies enrolling healthy and diseased subjects with a device specifically tailored to record bowel sounds are needed to generalize these results and determine their application in the patient population.
Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS) cohort
Polsinelli, Angelina J. , Wonderlin, Ryan J., Hammers, Dustin B. , Garcia, Alex Pena, Eloyan, Ani , Taurone, Alexander, Thangarajah, Maryanne, Gao, Sujuan , Kirby, Kala, Logan, Paige E. , Aisen, Paul , Dage, Jeffrey L. , Griffin, Percy , Kramer, Joel H. , Kukull, Walter A. , Joie, Renaud La , Mundada, Nidhi S. , Soleimani‐Meigooni, David N. , Rumbaugh, Malia, Touroutoglou, Alexandra , Vemuri, Prashanthi , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Steven, Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S. , Carrillo, María C. , Rabinovici, Gil D. , Apostolova, Liana G. , Vemuri, Prashanthi , Day, Gregory S , La Joie, Renaud , Rabinovici, Gil D , Wingo, Thomas S , Dage, Jeffrey L , Hammers, Dustin B , Beckett, Laurel , Wang, Sophia , Kirby, Kala, Foroud, Tatiana , Iaccarino, Leonardo , Koeppe, Robert A. , Murray, Melissa E. , Nudelman, Kelly , Toga, Arthur W. , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Womack, Kyle , Musiek, Erik , Salloway, Steve , Wolk, David A. , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | June 9, 2023 | Volume: 19 | Issue: S9 | Pages: No page available

10.1002/alz.13344 | PMID 37296082 Get It

AbstractIntroductionWe examined neuropsychiatric symptoms (NPS) and psychotropic medication use in a large sample of individuals with early‐onset Alzheimer's disease (EOAD; onset 40‐64 years) at the midway point of data collection for the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS).MethodsBaseline NPS (Neuropsychiatric Inventory – Questionnaire; Geriatric Depression Scale) and psychotropic medication use from 282 participants enrolled in LEADS were compared across diagnostic groups – amyloid‐positive EOAD (n = 212) and amyloid negative early‐onset non‐Alzheimer's disease (EOnonAD; n = 70).ResultsAffective behaviors were the most common NPS in EOAD at similar frequencies to EOnonAD. Tension and impulse control behaviors were more common in EOnonAD. A minority of participants were using psychotropic medications, and use was higher in EOnonAD.DiscussionOverall NPS burden and psychotropic medication use were higher in EOnonAD than EOAD participants. Future research will investigate moderators and etiological drivers of NPS, and NPS differences in EOAD versus late‐onset AD.
Multicohort Study of Conditional Survival and Cause of Death After Achieving Event‐Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL)
Wang, Y., Ekberg, Sara , Smedby, Karin E. , Zhao, Ergang, Nowakowski, G. S., Albertsson‐Lindblad, Alexandra , Wang, Yucai , Larson, Melissa C. , Gerrie, Alina S. , Farooq, Umar , Maurer, Matthew J. , Paludo, Jonas , Habermann, Thomas M. , Glimelius, Ingrid , Link, Brian K. , Diego, V., Jerkeman, Mats , Cerhan, James R.

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 472-474

10.1002/hon.3164_347 Get It

Comparison of clinical outcomes in patients with relapsed/refractory large B‐cell lymphoma treated with epcoritamab versus chemoimmunotherapy
Mutebi, Alex , Wang, T., Ma, Jun , Wang, A., Yu, Jinhua , Brodkin, Samantha, Kalsekar, Anupama, Ip, Andrew , Rosenthal, Allison , Wang, Trent , Yu, J., Sacchi, M., Muñoz, Javier

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 433-434

10.1002/hon.3164_319 Get It

Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory or early relapsing diffuse large B‐cell lymphoma (DLBCL)
Bock, Allison M. , Mwangi, Raphael , Shreve, J. T., Khurana, Arushi , Wang, Y., Nowakowski, Grzegorz S. , Young, Joseph , Ataei, F., Thorpe, Matthew , Pritchett, Joshua C. , Maurer, Matthew J. , Paludo, Jonas , Cerhan, James R. , Witzig, Thomas E. , Habermann, Thomas M. , Young, J. R.

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 344-345

10.1002/hon.3164_246 Get It

Automated FDG PET/CT radiomics for risk stratification in newly diagnosed diffuse large B‐cell lymphoma (DLBCL)
Shreve, Jacob , Bock, Allison M. , Shah, M. V., Wang, Y., Nowakowski, Grzegorz S. , Novak, Anne J. , Young, Jason R., Ansell, Stephen M. , Hazim, Antonious , Pritchett, Joshua C. , Maurer, Matthew J. , Binder, Moritz , Witzig, Thomas E. , Cerhan, James R. , Habermann, Thomas M. , Paludo, Jonas

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 341-342

10.1002/hon.3164_244 Get It

COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB‐BASED REGIMENS, AND TAFASITAMAB‐BASED REGIMENS
Jun, Mira , Wang, T., Mutebi, Alex , Wang, A., Osei-Bonsu, Kojo, Elliott, Brian , Kalsekar, Anupama, Navarro, Fátima, Rosenthal, Allison , Jun, M., Muñoz, Javier , Wang, Trent , Su, Yang , Navarro, F. Rivas, Ip, Andrew

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 790-792

10.1002/hon.3165_639 Get It